VMY 1-103

CAS NO.：1209002-43-6
Empirical Formula: C34H42ClN9O4S
Molecular Weight: 708.27
SAFETY DATA SHEET (SDS)
Update Date: 2026-01-05 11:31:08

What is VMY 1-103?

Description

VMY-1-103 is a potent CDK inhibitor, is also a novel dansylated analog of purvalanol B, was shown to inhibit cell cycle progression and proliferation in prostate and breast cancer cells more effectively than purvalanol B. VMY-1-103 , but not purvalanol B, significantly decreased the proportion of cells in S phase and increased the proportion of cells in G(2)/M. VMY-1-103 increased the sub G(1) fraction of apoptotic cells, induced PARP and caspase-3 cleavage and increased the levels of the Death Receptors DR4 and DR5, Bax and Bad while decreasing the number of viable cells, all supporting apoptosis as a mechanism of cell death. VMY-1-103 possesses unique antiproliferative capabilities and that this compound may form the basis of a new candidate drug to treat medulloblastoma.

Properties of VMY 1-103

Density	1.39±0.1 g/cm3(Predicted)
pka	10.91±0.50(Predicted)

Safety information for VMY 1-103

Computed Descriptors for VMY 1-103

New Products

Mirtazapine Impurity C/Mirtazapine Lactam Impurity N,O-Dimethylhydroxylamine hydrochloride Tetrabutylammonium perchlorate N,N CARBONYL DIIMIDAZOLE 2-Amino-5-bromo-4-(trifluoromethyl)pyridine（RM for Indian lab) (RS)-beta-Amino-beta-(4-bromophenyl)propionic acid (R)-1-Benzyl-3-pyrrolidinecarbonitrile N-Nitroso hydroxy Cetrizine EP Impurity-A Noradrenaline EP Impurity D/Noradrenaline Methyl Ether Cetirizine EP Impurity A/Cetirizine CBHP Impurity Lantanoprost rc B Clidinium Bromide Impurity 2,2'-(5-methyl-1,3-phenylene)-di(2-Methylpropionitrile) 1-methyl amino-2,4-dinitro benzene 5-Methyl-1,3-benzenediacetonitrile 4-Fluorothiophenol (R)-BoroLeu-(+)-Pinanediol-CF3COOH 4-(5-amino-1-methyl-1h-benzoimidazol-2-yl)-butyric acid isopropyl ester. 3,4 Diethoxy Benzylcyanide 2-Chloro Benzylcyanide 3-chlorobenzyl cyanide 3,4 Dimethoxy Benzylcyanide valeronitrile 4-Bromo Benzylcyanide